645 related articles for article (PubMed ID: 16763281)
1. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
4. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
5. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
Thomas SM; Coppelli FM; Wells A; Gooding WE; Song J; Kassis J; Drenning SD; Grandis JR
Cancer Res; 2003 Sep; 63(17):5629-35. PubMed ID: 14500405
[TBL] [Abstract][Full Text] [Related]
7. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Astsaturov I; Cohen RB; Harari P
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
[TBL] [Abstract][Full Text] [Related]
8. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Cooper JB; Cohen EE
Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
13. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.
Patel V; Rosenfeldt HM; Lyons R; Servitja JM; Bustelo XR; Siroff M; Gutkind JS
Carcinogenesis; 2007 Jun; 28(6):1145-52. PubMed ID: 17234718
[TBL] [Abstract][Full Text] [Related]
14. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor.
Lui VW; Thomas SM; Zhang Q; Wentzel AL; Siegfried JM; Li JY; Grandis JR
Oncogene; 2003 Sep; 22(40):6183-93. PubMed ID: 13679857
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
18. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
20. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]